N-benzyl-2-bromo-4-nitrobenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-2-bromo-4-nitrobenzamide
• 化学式: C₁₄H₁₁BrN₂O₃
• 分子量: 335.157
• InChiKey: QUTUZEDLQJJOPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-benzyl-2-bromo-4-nitrobenzamide 在 tin(II) chloride dihdyrate 、 碳酸氢钠 作用下， 以 乙酸乙酯 、 水 为溶剂， 反应 2.0h， 以96%的产率得到4-amino-N-benzyl-2-bromobenzamide
  参考文献：
  名称：

  Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein

  摘要：

  Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STAT3-mediated molecular events that support the malignant phenotype. To identify novel, STAT3-selective inhibitors suitable for interrogating STAT3 signaling in tumor cells, we explored the design of hybrid molecules by conjugating a known STAT3 inhibitory peptidomimetic, ISS610 to the high-affinity STAT3-binding peptide motif derived from the ILR/gp-130. Several hybrid molecules were examined in in vitro biophysical and biochemical studies for inhibitory potency against STAT3. Lead inhibitor 14aa was shown to strongly bind to STAT3 (K-D = 900 nM), disrupt STAT3: phosphopeptide complexes (K-i = 5 mu M) and suppress STAT3 activity in in vitro DNA binding activity/electrophoretic mobility shift assay (EMSA). Moreover, lead STAT3 inhibitor 14aa induced a time-dependent inhibition of constitutive STAT3 activation in v-Src transformed mouse fibroblasts (NIH3T3/v-Src), with 80% suppression of constitutively-active STAT3 at 6 h following treatment of NIH3T3/v-Src. However, STAT3 activity recovered at 24 h after treatment of cells, suggesting potential degradation of the compound. Results further showed a suppression of aberrant STAT3 activity in NIH3T3/v-Src by the treatment with compound 14aa-OH, which is the non-pTyr version of compound 14aa. The effect of compounds 14aa and 14aa-OH are accompanied by a moderate loss of cell viability. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.010
• 作为产物：
  描述：

  2-溴-4-硝基苯甲酸 在 草酰氯 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.42h， 生成 N-benzyl-2-bromo-4-nitrobenzamide
  参考文献：
  名称：

  Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein

  摘要：

  Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STAT3-mediated molecular events that support the malignant phenotype. To identify novel, STAT3-selective inhibitors suitable for interrogating STAT3 signaling in tumor cells, we explored the design of hybrid molecules by conjugating a known STAT3 inhibitory peptidomimetic, ISS610 to the high-affinity STAT3-binding peptide motif derived from the ILR/gp-130. Several hybrid molecules were examined in in vitro biophysical and biochemical studies for inhibitory potency against STAT3. Lead inhibitor 14aa was shown to strongly bind to STAT3 (K-D = 900 nM), disrupt STAT3: phosphopeptide complexes (K-i = 5 mu M) and suppress STAT3 activity in in vitro DNA binding activity/electrophoretic mobility shift assay (EMSA). Moreover, lead STAT3 inhibitor 14aa induced a time-dependent inhibition of constitutive STAT3 activation in v-Src transformed mouse fibroblasts (NIH3T3/v-Src), with 80% suppression of constitutively-active STAT3 at 6 h following treatment of NIH3T3/v-Src. However, STAT3 activity recovered at 24 h after treatment of cells, suggesting potential degradation of the compound. Results further showed a suppression of aberrant STAT3 activity in NIH3T3/v-Src by the treatment with compound 14aa-OH, which is the non-pTyr version of compound 14aa. The effect of compounds 14aa and 14aa-OH are accompanied by a moderate loss of cell viability. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.010

文献信息

• Palladium-Catalyzed Annulation of Arynes by <i>o</i>-Halobenzamides: Synthesis of Phenanthridinones
  作者：Chun Lu、Anton V. Dubrovskiy、Richard C. Larock

  DOI：10.1021/jo3016192

  日期：2012.10.5

  The palladium-catalyzed annulation of arynes by substituted o-halobenzamides produces N-substituted phenanthridinones in good yields. This methodology provides this important heterocyclic ring system in a single step by simultaneous C–C and C–N bond formation, under relatively mild reaction conditions, and tolerates a variety of functional groups.

  通过取代的邻卤代苯甲酰胺钯催化的芳炔环化以良好的产率产生N-取代的菲啶酮。该方法通过在相对温和的反应条件下同时形成 C-C 和 C-N 键，一步提供了这种重要的杂环系统，并且可以耐受多种官能团。
• Assembly of Substituted 3-Methyleneisoindolin-1-ones via a CuI/<scp>l</scp>-Proline-Catalyzed Domino Reaction Process of 2-Bromobenzamides and Terminal Alkynes
  作者：Li Li、Miao Wang、Xiaojing Zhang、Yongwen Jiang、Dawei Ma

  DOI：10.1021/ol9000922

  日期：2009.3.19

  CuI/L-proline catalyzed coupling of 2-bromobenzamides and terminal alkynes in PrOH (or DMF and DMSO) at 85-110 degrees C and subsequent additive cyclization produces substituted 3-methyleneisoindolin-1-ones. Variation of N-substituents, aromatic ring, and methylene part is possible by using suitable starting materials.
• 10.15227/orgsyn.99.0159
  作者：Witkowski, Dominick C.、McDermott, Luca、Garg, Neil K.

  DOI：10.15227/orgsyn.99.0159

  日期：——